Clinical Trial Search

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Progression-free Survival — 25 months

Primary: Overall Survival — 32 months

Primary: Number of Participants With Treatment Success — 23 Participants

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…

Primary: Progression-free Survival — 11.0; 12.3; 15.3 months — p=0.448

Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001

Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065

Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Progression Free Survival (PFS) — 15.4; 14.3 Months — p=0.31

Primary: Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in…

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Quality of Life (QOL) Assessed Using Functional Assessment of Cancer Therapy-Ovarian Questionnaire (FACT-O) — 116.32 score on a scale

Primary: Objective Tumor Response — 4; 8; 8; 32 Participants

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Objective Response Rate (ORR) — 2; 0 Participants

Primary: Tumor Response — 23.4 Percentage of participants

Primary: Progression-free Survival — 2.6; 2.9 months

Primary: 6 Month Progression Free Survival — 0 Participants

Primary: Objective Tumor Response — 21; 32; 17; 1 participants